EDITORIAL BOARD INSTRUCTIONS TO AUTHORS PUBLISHED ISSUES MANUSCRIPT SEARCH

Nish İstanbul A Blok Kat: 8 No: 47-48 Çobançeşme, Sanayi Cd. 11, Yenibosna, Bahçelievler 34196 İstanbul-Turkey

Tel

+90 (212) 221 17 30
+90 (212) 221 17 38

Fax

+90 (212) 221 17 54



Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2013; 41:166-171   PMID: 23666308

  Volume: 41  Issue: 2 March 2013   
TKD|Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents

Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents

Akut koroner sendromların yeni antitrombosit ilaçlar ile tedavi stratejisinde öne çıkan konular

Dr. Rasim Enar


    Summary: The novel oral P2Y12 inhibitors (prasugrel and ticagrelor) have been incorporated into the recently updated acute coronary syndrome (ACS) guidelines, as an adjunct antiplatelet treatment to aspirin. The studies involving the use of new oral antiplatelet agents that are more potent, predictable and faster platelet inhibitors than clopidogrel have demonstrated superiority with respect to the primary composite endpoint (cardiovascular death, non-lethal myocardial infarction, stroke) for both prasugrel and ticagrelor compared to clopidogrel. The subgroup analysis of the relevant studies showed that these new agents differ in their level of efficacy in different ACS patient subgroups: (1) Mortality was reduced with ticagrelor; (2) Ticagrelor is especially more effective in intermediate-and high-risk non-ST elevation ACS patients in whom early invasive strategy is selected; (3) Prasugrel should be especially preferred in patients with acute ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) after diagnostic angiography; and (4) Prasugrel is more effective in diabetic patients. While clopidogrel is recommended for ACS patients who are followed with a non-invasive strategy or who have not undergone percutaneous revascularization, it is the last line choice or an alternative to the P2Y12 inhibitor therapy for patients undergoing invasive strategy



 
   
2014 © All rights reserved. Turkish Society of Cardiology.

 LookUs & Online Makale